What 22 Analyst Ratings Have To Say About Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Over the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has received 22 analyst ratings, with 7 being bullish, 10 somewhat bullish, and 5 indifferent. The average 12-month price target for the company is $133.59, which has increased by 4.42% over the past month.
October 06, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has received mostly positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings are a significant factor that investors consider when making investment decisions. The predominantly positive ratings for Neurocrine Biosciences indicate a positive outlook for the company, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100